Global RSV Vaccine Market Size, Share, and COVID-19 Impact Analysis, By Types of Vaccine (Subunit / Viral-like-Particle (VLP) Vaccines, Live Attenuated Vaccines, and mRNA Vaccines), By Distribution Channel (Pharmacies and Drug Stores, Government / Institutional Suppliers and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global RSV Vaccine Market Insights Forecasts to 2035

• The Global RSV Vaccine Market Size Was Estimated at USD 1.47 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.14% from 2025 to 2035
• The Worldwide RSV Vaccine Market Size is Expected to Reach USD 2.55 Billion by 2035
• Asia Pacific is Expected to Grow the fastest during the forecast period.

The Global RSV Vaccine Market Size was Worth Around USD 1.47 Billion in 2024 and is Predicted to Grow to around USD 2.55 Billion by 2035 with a Compound Annual Growth Rate (CAGR) of 5.14% from 2025 to 2035. The Market Size is Growing due to government programs and healthcare organizations' efforts to promote immunization and increase public knowledge of the health hazards associated with RSV, which opens doors for vaccine developers and producers.

Market Overview

The worldwide sector devoted to the creation, manufacturing, and distribution of vaccinations that target the respiratory syncytial virus (RSV) is known as the RSV vaccine market. It includes a variety of vaccination forms, such as live attenuated, subunit, and mRNA vaccines, which are delivered via intramuscular injections and other methods. RSV vaccines work by boosting the immune system's ability to identify and combat the respiratory syncytial virus, hence preventing infections and other serious respiratory conditions, including pneumonia and bronchitis.  

The inclusion of RSV vaccines in childhood immunization regimens and the growing focus on pediatric vaccination programs present a significant market opportunity. For Instance, in May 2024, Moderna, Inc. announced that mRESVIA (mRNA-1345), an mRNA respiratory syncytial virus (RSV) vaccine, was recently approved by the U.S. Food and Drug Administration (FDA) to prevent lower respiratory tract disease in individuals 60 years of age and older due to RSV infection.   

The increased awareness of preventive RSV vaccines, technological developments including the use of mRNA and vector-based technologies, and the increased incidence of RSV infections are driving the market trend for RSV vaccines. Increased awareness of RSV vaccination, the growing global incidence of RSV disorders, and technological developments in vaccine development are expected to drive market expansion.

Report Coverage

This research report categorizes the RSV vaccine market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the RSV vaccine market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the RSV vaccine market. 

Driving Factors

The significant disease burden linked to RSV infections motivates the development and broad use of RSV vaccines, which are intended to lessen the incidence, seriousness, and socioeconomic in RSV-related illnesses. The high incidence of RSV infections, particularly in susceptible groups like the elderly and newborns, provides a compelling incentive for the development of vaccines and the expansion of the RSV vaccine market. Rising hospitalization rates from RSV, growing awareness of the virus's negative health effects, particularly for young children and the elderly, and continuous improvements in vaccine technology are some of the major factors that drive the RSV vaccine market.   

Restraining Factors

High development costs, strict regulatory approvals, little awareness, supply chain limitations, and competition from other therapies are some of the challenges facing the RSV vaccine market. Moreover, geographical differences and vaccination reluctance restrict RSV vaccine market growth.

Market Segmentation

The RSV Vaccine market share is classified into type of vaccine and distribution channel.   

• The subunit / viral-like-particle (VLP) vaccines segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the type of vaccine, the RSV vaccine market is divided into subunit / viral-like-particle (VLP) vaccines, live attenuated vaccines, and mRNA vaccines. Among these, the subunit / viral-like-particle (VLP) vaccines segment dominated the market in 2024 and is projected to grow at a substantial CAGR during the forecast period. Subunit and viral-like particle vaccinations are safer and more effective due to these characteristics, which also drastically lower the toxicity and possible adverse effects of conventional vaccines.

• The pharmacies and drug stores segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the distribution channel, the RSV vaccine market is divided into pharmacies and drug stores, government / institutional suppliers, and others. Among these, the pharmacies and drug stores segment accounted for the largest share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. The primary drivers of pharmacies and drug stores existence are accessibility and convenience, as most people reside near these establishments. Further, improved patient education and increased vaccination uptake have resulted from pharmacists being granted more authority to give vaccines.  

Regional Segment Analysis of the RSV Vaccine Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the RSV vaccine market over the predicted timeframe.

North America is anticipated to hold the largest share of the RSV vaccine market over the predicted timeframe. The increased incidence of respiratory illnesses during RSV seasons, North America's sophisticated healthcare system, and its strong regulatory frameworks are all factors in this region. North America, which includes the US and Canada, takes center stage. The expansion of childhood immunization campaigns, the incorporation of advanced vaccine technologies, and a determined attempt to reduce hospitalizations linked to RSV are some of the current market dynamics.

Asia Pacific is expected to grow at a rapid CAGR in the RSV vaccine market during the forecast period. Growing awareness, the development of healthcare infrastructure, and government-led initiatives are all contributing to the spike in demand for RSV vaccines in the Asia-Pacific region. Notable developments in this region include a greater focus on childhood immunization and ongoing improvements in vaccine technology, both of which are critical drivers of market expansion.  

Europe is predicted to hold a significant share of the RSV vaccine market throughout the estimated period. Europe represents all of the European countries' combined efforts to fight RSV infections in the context of the RSV vaccine market. Current market trends demonstrate a growing commitment to respiratory health, including a greater focus on pediatric RSV immunization, the use of advanced vaccine technologies, and regulatory approvals for RSV vaccines.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the RSV vaccine market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Pfizer Inc.
• Moderna Inc.
• Sanofi
• Novavax Inc.
• AstraZeneca plc
• Merck & Co. Inc.
• GlaxoSmithKline
• Beijing Advaccine Biotechnology
• GlaxoSmithKline plc (GSK)
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Development

• In April 2025, Pfizer Inc. announced that the European Commission (EC) updated the marketing authorization for its bivalent respiratory syncytial virus (RSV) prefusion F (RSVpreF) vaccine, ABRYSVO, to include the prevention of lower respiratory tract disease (LRTD) caused by RSV in people aged 18 to 59.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the RSV vaccine market based on the below-mentioned segments: 

Global RSV Vaccine Market, By Type of Vaccine

• Subunit / Viral-like-Particle (VLP) Vaccines
• Live Attenuated Vaccines
• mRNA Vaccines

Global RSV Vaccine Market, By Distribution Channel

• Pharmacies and Drug Stores
• Government / Institutional Suppliers
• Others

Global RSV Vaccine Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa